Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We rightly hear a lot about Oxford’s vaccine, Covid-19 research and RECOVERY drug trials, but there are also countless personal stories, which display just how broad Oxford’s response to the pandemic has been. It is the contribution and commitment of many individuals that has enabled Oxford’s Medical Sciences Division to become a global leader.

Will Watson and Matt Bottomley
Will Watson (left) and Matt Bottomley (right)

Will WatsonWill Watson is a Cardiology Clinical Research Training Fellow & DPhil student in Radcliffe Department of Medicine. His research project, like many others, was put on hold when Covid-19 hit and he was asked to work from home. After a couple of weeks, he got the opportunity to be redeployed back to a clinical role in intensive care medicine to support the NHS response.

Will moved out of home as the force of the first wave of the pandemic hit in spring 2020. At the time, the horror stories from China and Italy made it clear that the situation was incredibly serious. Will recalled a vivid memory of packing up his car ready to leave Oxford and looking back at his house, wondering if he’d see it again.

In the hospital, there were challenges and losses. Will described a feeling of powerlessness amongst ICU teams as the virus claimed more people, despite receiving highly specialised intensive care. The lack of science and evidence to guide treatment added to this feeling – the virus was new, there were no experts and no proven treatments. So, the day that Oxford announced its trial results about the efficacy of dexamethasone for patients in intensive care was a very good day! To have a clinically proven drug was a huge step forward and gave him a huge sense of pride.

Will feels that his outlook on life has changed due to his experiences earlier this year. He’s living in the moment more, keeping closer contact with friends and feeling lucky to be healthy and to have been in a position to help. He’s fully prepared to go back and help again if his services are needed but also looks forward to getting back to his research at Oxford, which has been approved to restart.

Matt BottomleyMatt Bottomley is a Clinical Postdoctoral Researcher in Nuffield Department of Surgical Sciences, working as a Lecturer and Renal Registrar with a role that is, in normal times, 50% clinical and 50% research. Matt became aware that clinical redeployment was needed in March and, as he had trained as a doctor, he felt it was the right thing for him to do in the nation’s time of need and agreed to return to full-time clinical practice.

For Matt, as a renal specialist, he was working as part of a team in the Churchill and John Radcliffe Hospitals to manage patients with kidney problems, either pre-existing or as a result of Covid. He describes looking after vulnerable immune suppressed patients and working in new ways to protect them from infection. Renal patients need dialysis, often several times a week, so the team set up a separate dialysis unit for patients with COVID to reduce the risk of transmission. Where possible, they also temporarily reduced the number of times a patient came in for dialysis to reduce contact and risk. However, they saw a lot of patients coming in with new kidney problems who were very sick, as they had been unable or unwilling to attend their doctor due to fears about catching Covid.

Matt recalls the devastating impact Covid had on some patients. He vividly remembers one patient - a previously healthy, middle-aged man who had been completely incapacitated by Covid. The patient needed renal support due to the serious effect of Covid on his body and he became so weak that he was unable to even move himself from bed to a chair. After a long spell in hospital and with intensive rehabilitation, Matt was delighted that the patient did finally recover and go home with a good outcome. Many patients were not as lucky.

Some of the team at the renal unit are now involved in Covid-focused research looking at biomarkers in renal patients to predict outcomes. This is still recruiting and is continuing during the current surge in cases. Matt is currently catching up with his own research project alongside working on the frontline in general medicine during this current wave. Matt and his wife also welcomed their new baby in December!

Oxford continues to make a huge impact in the fight against Covid-19. As well as the vital vaccine work and drug research that continues apace, many of our researchers have put their own research on hold and selflessly put themselves on the ‘frontline’. We have never been more proud to be part of community contributing such great things to the global pandemic response.

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.